Fenwick’s ESG Report Cited on Expanding Climate Action Initiatives in Pharma and Biotech Companies

Fenwick corporate partner Julia Forbess and counsel Ron Llewellyn authored an environmental, social and governance (ESG) report which was featured in an article by STAT.

The article discusses the growing focus among pharma and biotech companies to address their responsibility in the impacts of climate change. Driven by sector demands and climate change realities, an increasing percentage of biotech and large pharma companies have now taken or pledge to take impactful ESG measures. 

Fenwick’s 2022 “Biotech ESG Crossroads” reports on the future role of ESG practices in biotech companies. The report anticipates significantly more ESG reporting by these companies and higher industry standards concerning environmental sustainability in the coming years based on insights from 100 executives at major biotech companies as well as representatives of investment banks, venture capital firms and hedge funds.

Read the full article here.